BioAtla (NASDAQ:BCAB) Announces Earnings Results, Beats Estimates By $0.01 EPS

BioAtla (NASDAQ:BCAB) posted its earnings results on Thursday. The company reported ($0.44) earnings per share for the quarter, beating the consensus estimate of ($0.45) by $0.01, Zacks reports. During the same quarter last year, the business earned ($0.75) earnings per share.

BioAtla Stock Performance

NASDAQ:BCAB remained flat at $1.47 on Friday. 467,416 shares of the company’s stock traded hands, compared to its average volume of 679,873. The stock has a fifty day moving average price of $1.57 and a two-hundred day moving average price of $2.26. BioAtla has a 12 month low of $1.14 and a 12 month high of $4.02. The firm has a market capitalization of $70.73 million, a PE ratio of -0.59 and a beta of 1.06.

Analyst Upgrades and Downgrades

Several equities analysts have weighed in on the stock. HC Wainwright reiterated a “buy” rating and issued a $7.00 target price on shares of BioAtla in a report on Wednesday, May 15th. JMP Securities decreased their target price on shares of BioAtla from $12.00 to $5.00 and set a “market outperform” rating on the stock in a report on Thursday, May 23rd.

BioAtla Company Profile

BioAtla, Inc, a clinical-stage biopharmaceutical company, develops specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. The company's lead clinical stage product candidates include mecbotamab vedotin (BA3011), a conditionally active biologic (CAB) antibody-drug conjugate (ADC), which is in Phase II clinical trial for treating undifferentiated pleomorphic sarcoma and non-small cell lung cancer (NSCLC); and ozuriftabmab vedotin (BA3021), a CAB ADC that is in Phase II clinical trial for the treatment of melanoma and squamous cell cancer of the head and neck.